See all

2021 Updates: Lilly's Global COVID-19 Response

View Story

Supporting United Way to Meet New Challenges

View Story

Racial Justice Initiative: Confronting Racial Inequities Head On

View Story

How Digital and Remote Health Can Help Next-Generation VBAs

View Story

Meet the Women Behind Our Cancer Research

View Story

Christalyn Rhodes, Ph.D.

Christalyn Rhodes: Living Her Purpose, Our Purpose

View Story

Press Releases

See all

Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19

February 26, 2021

Tags |  Product

INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received

Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions

February 25, 2021

Tags |  Product

COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly 's connected insulin solutions, currently in development.

Lilly to Participate in Cowen Health Care Conference

February 24, 2021

Tags |  Financial

INDIANAPOLIS , Feb. 24, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41 st Annual Health Care Conference on Thursday, March 4, 2021 . Daniel Skovronsky , M.D., Ph.D., Lilly 's Chief Scientific Officer and President of Lilly Research Laboratories

Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases

February 18, 2021

Tags |  Corporate

- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications - Rigel will receive an upfront cash payment of $125 million, with the potential for up to an additional $835 million in future development, regulatory,